Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
RESEARCH TOOLSreports
2269 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$10.14 - HK$26.10
Previous CloseN/A
Volume35.71M
Average Volume (3M)61.85M
Market Cap
$98.98B
Enterprise ValueHK$48.05B
Total Cash (Recent Filing)¥9.67B
Total Debt (Recent Filing)¥4.56B
Price to Earnings (P/E)35.3
Beta1.72
Next Earnings
Mar 25, 2025EPS Estimate
0.47Last Dividend Ex-Date
Nov 02, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding4,107,040,000
10 Day Avg. Volume51,468,476
30 Day Avg. Volume61,845,475
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$24.95Price Target Upside3.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Wuxi Biologics (Cayman) News
PremiumCompany Announcements
WuXi Biologics Schedules Board Meeting for Annual Results Approval
PremiumCompany Announcements
WuXi Biologics Announces Hong Kong Office Relocation
PremiumCompany Announcements
Wuxi Biologics Sells Vaccines Ireland Facility for $500M
PremiumCompany Announcements
WuXi Biologics Welcomes New Non-Executive Director
PremiumCompany Announcements
WuXi Biologics Updates Board and Committees
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAntibody-drug conjugate and commercial deals provide stable recurring cash flows, with significant growth in projects.
Global ExpansionThe company has expanded its services overseas, reducing reliance on China and increasing its global footprint.
Bears Say
Regulatory RisksThe Biosecure Act poses a long-term risk to more than 50% of WuXi Biologics' business in the US.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.65% Mutual Funds
0.02% Other Institutional Investors
87.63% Public Companies and
Individual Investors
2269 FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was HK$10.14 and its highest was HK$26.10 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Wuxi Biologics (Cayman) Inc.’s market cap is $98.98B.
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Mar 25, 2025 which is in 12 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Aug 21, 2024. The company reported HK$0.375 earnings per share for the quarter, missing the consensus estimate of HK$0.439 by -HK$0.064.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. pays a Notavailable dividend of HK$0.054 which represents an annual dividend yield of N/A. See more information on Wuxi Biologics (Cayman) Inc. dividends here
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.47.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,107,040,000 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.375 in its last earnings report, missing expectations of HK$0.439. Following the earnings report the stock price went down -2.906%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Currently, no hedge funds are holding shares in HK:2269
---
Wuxi Biologics (Cayman) Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$24.95 (3.51% Upside)
HK$24.95 (3.51% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.17%
12-Months-Change
Fundamentals
Return on Equity
6.75%
Trailing 12-Months
Asset Growth
7.57%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman) Inc.
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
---
2269 Stock 12 Month Forecast
Average Price Target
HK$24.95
▲(3.51% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Luye Pharma Group
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering 2269
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+20.18%
reiterated a buy rating last month
Copying Michael Luo CFA's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +20.18% per trade.
---